FDA approves new type of nonopioid painkiller for acute pain
The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
FDA approves new medication as alternative to opioids for pain treatment
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.
FDA approves pain medication
Whether you’re cleaning your kitchen after a big meal or finishing a painting project, it can be tempting to pour just about ...
ConsumerAffairs52m
A new non-opioid pain medication wins Food and Drug Administration approval
The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction of a first-in-class non-opioi ...
FDA OK's painkiller designed to end opioids' addiction and overdose risk
Federal officials approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with ...
Walmart Broccoli Recall Updated to ‘Deadly’ Risk—Here’s Why
The recalled Braga Fresh Marketside Broccoli was washed, ready-to-eat, and sold in 12-ounce bags at Walmart stores in 20 states including Alaska, Arkansas, Arizona, California, Colorado, Idaho, ...
FDA approves new painkiller designed to avoid opioid addiction risk
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The Hacker News1h
CISA and FDA Warn of Critical Backdoor in Contec CMS8000 Patient Monitors
Unpatched vulnerabilities in Contec CMS8000 patient monitors expose devices to remote access, file overwrites, and data leaks ...
Chocolate Recalled in 3 States Over Possible 'Life-Threatening' Reaction
A chocolate-covered pretzel product is being recalled in three states due to the presence of an undeclared milk allergen.
FDA Opens Up A New Path To The U.S. Market For This Under 30 Biotech Startup
More than 10 million babies have been born through IVF, yet the process is still invasive and costly. Plus, why a venture ...
FiercePharma1h
Fierce Pharma Asia—Takeda's next CEO; Enhertu's novel FDA nod; East Asian American C-suite execs
Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...